USFDA approves neurological drug from Zydus
With 160 ANDAs pending by the Zydus group, this is the 100th approval on the list
Zydus Cadila has received the green signal to market the Pyridostigmine Bromide Tablets USP, 60 mg. The approval comes from the US drug regulator, USFDA Â and is a milestone achievement for the company, as it strikes one more new drug approval from the total application of 260 filed till date.
This lucky number of 100th drug application (from over 260 ANDAs since the commencement of the filing process in FY 2003-04) approval, is estimated to generate a whopping sale of $27.9 million as per IMS. The drug in action is used for treatment of various neurological disorders
Zydus Cadila has received the green signal to market the Pyridostigmine Bromide Tablets USP, 60 mg. The approval comes from the US drug regulator, USFDA Â and is a milestone achievement for the company, as it strikes one more new drug approval from the total application of 260 filed till date.
This lucky number of 100th drug application (from over 260 ANDAs since the commencement of the filing process in FY 2003-04) approval, is estimated to generate a whopping sale of $27.9 million as per IMS. The drug in action is used for treatment of various neurological disorders
Next Story